HYPERTRIGLYCERIDEMIA THERAPEUTICS MARKET ANALYSIS

Market News

Global Hypertriglyceridemia Therapeutics Market- Key Developments

On March 22 2023, Regeneron Pharmaceuticals, Inc., a biotechnology company,  announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for children as young as 5 years old to control dangerously high levels of low-density lipoprotein cholesterol (LDL-C) caused by HoFH. Evkeeza was initially approved as an adjunct to other lipid-lowering therapies in those aged 12 years and older with HoFH.

In May 2022, APONTIS PHARMA Deutschland GmbH & Co. KG, a pharmaceutical company, specializing in Single Pills announced a new development cooperation with Develco Pharma Switzerland, a private company that develops and produces innovative formulations for drugs with known active ingredients. The object is the contract development of two Single Pills, each with a combination of two leading active ingredients for the treatment of cardiovascular diseases caused by the hyperlipidemia.

In January 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology company, and Ionis Pharmaceuticals, a biotechnology company that specializes in discovering and developing RNA-targeted therapeutics, announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).

In February 2021, Regeneron Pharmaceuticals, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first U.S. FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism.